http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#Head http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#assertion http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#provenance http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#pubinfo http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#assertion http://purl.obolibrary.org/obo/DOID_2449 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_2449 http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00104 http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association http://www.w3.org/2000/01/rdf-schema#label acromegaly octreotide acetate injection is indicated to reduce blood levels of growth hormone and igf i somatomedin c in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection pituitary irradiation and bromocriptine mesylate at maximally tolerated doses the goal is to achieve normalization of growth hormone and igf i somatomedin c levels see dosage and administration improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection these trials were not optimally designed to detect such effects carcinoid tumors octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases vasoactive intestinal peptide tumors vipomas octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with vip secreting tumors octreotide acetate injection studies were not designed to show an effect on the size rate of growth or development of metastases http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#association https://w3id.org/biolink/vocab/relation https://w3id.org/um/neurodkg/SymptomaticReliefIndication https://identifiers.org/drugbank:DB00104 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#provenance http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#pubinfo http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig http://purl.org/nanopub/x/hasSignature Qw/dxPFErxuvhc33KVNLgIUvGYXGpxkNVXngA2pZmdnOB+4kts/xgB/xc1dkiqId+3JvoqzIBoGhSroA7lnAjFMqwPN0mDwETVnZifAA8ARoujC/MLONmKJs0PVOaUjCUmQlbgI3QbZyUscNHw9OEkz25tVfG7zhz/3y2Qidd3s= http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://purl.org/dc/terms/created 2021-06-30T09:26:54.277+02:00 http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RA_YLsU-_9ReKinT_QyJOHbLAlnnvrAt6dPA37DgUQxRc https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs